Comparing LeMaitre Vascular (LMAT) & Its Peers
LeMaitre Vascular (NASDAQ: LMAT) is one of 86 public companies in the “Advanced Medical Equipment & Technology” industry, but how does it compare to its competitors? We will compare LeMaitre Vascular to similar businesses based on the strength of its earnings, valuation, profitability, risk, analyst recommendations, institutional ownership and dividends.
This is a breakdown of current recommendations and price targets for LeMaitre Vascular and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|LeMaitre Vascular Competitors||265||1862||3344||108||2.59|
Risk & Volatility
LeMaitre Vascular has a beta of 0.55, meaning that its share price is 45% less volatile than the S&P 500. Comparatively, LeMaitre Vascular’s competitors have a beta of 1.22, meaning that their average share price is 22% more volatile than the S&P 500.
Insider and Institutional Ownership
68.4% of LeMaitre Vascular shares are owned by institutional investors. Comparatively, 51.0% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 23.7% of LeMaitre Vascular shares are owned by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares LeMaitre Vascular and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|LeMaitre Vascular Competitors||-298.38%||-34.86%||-11.67%|
Earnings & Valuation
This table compares LeMaitre Vascular and its competitors top-line revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|LeMaitre Vascular||$89.15 million||$10.59 million||43.36|
|LeMaitre Vascular Competitors||$2.13 billion||$221.25 million||-30.39|
LeMaitre Vascular’s competitors have higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
LeMaitre Vascular pays an annual dividend of $0.22 per share and has a dividend yield of 0.7%. LeMaitre Vascular pays out 28.6% of its earnings in the form of a dividend. As a group, “Advanced Medical Equipment & Technology” companies pay a dividend yield of 0.8% and pay out 25.0% of their earnings in the form of a dividend. LeMaitre Vascular lags its competitors as a dividend stock, given its lower dividend yield and higher payout ratio.
LeMaitre Vascular competitors beat LeMaitre Vascular on 8 of the 15 factors compared.
LeMaitre Vascular Company Profile
LeMaitre Vascular, Inc. is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment. The Company’s product lines include valvulotomes, balloon catheters, carotid shunts, biologic vascular patches, radiopaque marking tape, anastomotic clips, remote endarterectomy devices, laparoscopic cholecystectomy devices, prosthetic vascular grafts, biologic vascular grafts and powered phlebectomy devices. Its portfolio of peripheral vascular devices consists of brand name products that are used in arteries and veins outside of the heart, including the Expandable LeMaitre Valvulotome, the Pruitt F3 Carotid Shunt, VascuTape Radiopaque Tape and the XenoSure biologic patch.
Receive News & Stock Ratings for LeMaitre Vascular Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular Inc. and related stocks with our FREE daily email newsletter.